首页> 外文OA文献 >PCN12 Comparison of Mean Overall Survival (OS) and Radiographic Progression Free Survival (RPFS) Based on Matching Adjusted Indirect Comparison of Abiraterone Acetate and Enzalutamide for the Treatment of Castration-Resistant Prostate Cancer in Chemotherapy Naïve Patients

【2h】

PCN12 Comparison of Mean Overall Survival (OS) and Radiographic Progression Free Survival (RPFS) Based on Matching Adjusted Indirect Comparison of Abiraterone Acetate and Enzalutamide for the Treatment of Castration-Resistant Prostate Cancer in Chemotherapy Naïve Patients

机译：基于匹配的间接比较醋酸阿比特龙酯和恩扎鲁胺治疗未接受去势的前列腺癌患者的PCN12平均总生存期（OS）和放射学无进展生存期（RPFS）的比较

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
引文网络
相似文献
相关主题

著录项

作者
Dearden L.; Majer I.; Heeg B.; Liwing J.; Sandstrom K.; Diels J.;
展开▼
作者单位

展开▼
年度 2014
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献
专利

1. Comparison of Radiographic Progression-Free Survival and PSA Response on Sequential Treatment Using Abiraterone and Enzalutamide for Newly Diagnosed Castration-Resistant Prostate Cancer: A Propensity Score Matched Analysis from Multicenter Cohort [J] . Kazumasa Komura, Yuya Fujiwara, Taizo Uchimoto, Journal of Clinical Medicine . 2019,第8期

机译：放射治疗无进展生存率和PSA对阿比特龙和恩杂鲁胺序贯治疗新诊断的去势抵抗性前列腺癌的反应比较：多中心队列的倾向得分匹配分析
2. Independent association between time to prostate-specific antigen (PSA) nadir and PSA progression-free survival in patients with docetaxel-naive, metastatic castration-resistant prostate cancer receiving abiraterone acetate, but not enzalutamide [J] . Miyake Hideaki, Hara Takuto, Tamura Keita, Urologic oncology . 2017,第6期

机译：在多西紫杉醇 - 幼稚园，转移性阉割的前列腺癌患者接受醋酸盐的患者的患者的患者中，抗原抗原（PSA）Nadir和PSA无进展生存之间的独立关联。
3. The effects of enzalutamide and abiraterone on skeletal related events and bone radiological progression free survival in castration resistant prostate cancer patients: An indirect comparison of randomized controlled trials [J] . Sergio Rizzo, Antonio Galvano, Francesco Pantano, Critical reviews in oncology/hematology . 2017,第期

机译：依甲醛酰胺和ABIRATERONE对抗腐蚀前列腺癌患者骨骼相关事件和骨放射进展免疫生存的影响：随机对照试验的间接比较
4. Ten-year Biochemical Disease-free Survival After High-intensity Focused Ultrasound (HIFU) for Localized Prostate Cancer: Comparison with Four Different Generation Devices [C] . T. Uchida, M. Nakano, S. Shoji, International Symposium on Therapeutic Ultrasound (2002- ) . 2010

机译：高强度聚焦超声（HIFU）局部前列腺癌的10年生化无病生存：与四种不同一代装置的比较
5. A Retrospective Study of Overall Survival and Metastasis-Free Survival of Adults with Osteosarcoma and Comparison to Pediatric Treatment Outcomes [D] . Berk, Tucker Kaneharu. 2020

机译：骨肉瘤成人整体存活和无转移存活的回顾性研究，与儿科治疗结果相比
6. Comparison of Radiographic Progression-Free Survival and PSA Response on Sequential Treatment Using Abiraterone and Enzalutamide for Newly Diagnosed Castration-Resistant Prostate Cancer: A Propensity Score Matched Analysis from Multicenter Cohort [O] . Kazumasa Komura, Yuya Fujiwara, Taizo Uchimoto, 2019

机译：放射治疗无进展生存率和PSA对阿比特龙和恩杂鲁胺序贯治疗新诊断的去势抵抗性前列腺癌的反应比较：多中心队列的倾向得分匹配分析
7. MP22-07 INDIRECT COMPARISON OF SURVIVAL AND COST PER NUMBER NEEDED TO TREAT TO BENEFIT ANALYSIS OF ABIRATERONE, ENZALUTAMIDE, AND SIPULEUCEL-T IN THE TREATMENT OF METASTATIC CASTRATION-RESISTANT PROSTATE CANCER [O] . Scott C. Flanders, Ben H. Lowentritt, Jason M. Hafron, 2019

机译：在治疗转移阉割前列腺癌的治疗中，治疗血液酮，依甲酰胺和西普尔-T的效益分析所需的存活率和成本间接比较。

PCN12 Comparison of Mean Overall Survival (OS) and Radiographic Progression Free Survival (RPFS) Based on Matching Adjusted Indirect Comparison of Abiraterone Acetate and Enzalutamide for the Treatment of Castration-Resistant Prostate Cancer in Chemotherapy Naïve Patients

著录项

引文网络

相似文献

相关主题

期刊订阅